Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience

European Urology

Volumn 61, Issue 4, 2012, Pages 705-711

  Efstathiou, Jason A ^a   Spiegel, Daphna Y ^a   Shipley, William U ^a   Heney, Niall M ^a   Kaufman, Donald S ^a   Niemierko, Andrzej ^a   Coen, John J ^a   Skowronski, Rafi Y ^a   Paly, Jonathan J ^a   McGovern, Francis J ^a   Zietman, Anthony L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bladder cancer; Chemotherapy; Combined modality therapy; Cystectomy; Radiation therapy

Indexed keywords

CISPLATIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BOSTON; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HOSPITALS, GENERAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 84857658866     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.11.010     Document Type: Article

References (30)

1. S.M. Donat, A. Shabsigh, and C. Savage Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience Eur Urol 55 2009 177 186
2. D.S. Kaufman, W.U. Shipley, P.P. Griffin, N.M. Heney, A.F. Althausen, and J.T. Efird Selective bladder preservation by combination treatment of invasive bladder cancer N Engl J Med 329 1993 1377 1382 (Pubitemid 23317347)
3. C. Rodel, G.G. Grabenbauer, and R. Kuhn Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results J Clin Oncol 20 2002 3061 3071 (Pubitemid 34791095)
4. W. Tester, A. Porter, and S. Asbell Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12 Int J Radiat Oncol Biol Phys 25 1993 783 790 (Pubitemid 23123381)
5. W. Tester, R. Caplan, and J. Heaney Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802 J Clin Oncol 14 1996 119 126 (Pubitemid 26020004)
6. W.U. Shipley, K.A. Winter, and D.S. Kaufman Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 J Clin Oncol 16 1998 3576 3583 (Pubitemid 28506771)
7. D.S. Kaufman, K.A. Winter, and W.U. Shipley The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response Oncologist 5 2000 471 476
8. W.U. Shipley, D.S. Kaufman, and E. Zehr Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer Urology 60 2002 62 67 (Pubitemid 34722947)
9. M.P. Hagan, K.A. Winter, and D.S. Kaufman RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy Int J Radiat Oncol Biol Phys 57 2003 665 672 (Pubitemid 37194292)
10. D.S. Kaufman, K.A. Winter, and W.U. Shipley Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy Urology 73 2009 833 837
11. A.L. Zietman, W.U. Shipley, and D.S. Kaufman A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer [comment] J Urol 160 1998 1673 1677 (Pubitemid 128746736)
12. W.U. Shipley, D.S. Kaufman, N.M. Heney, A.F. Althausen, and A.L. Zietman An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy J Urol 162 1999 445 450 discussion 450-1
13. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675 (Pubitemid 32120143)
14. G. Dalbagni, E. Genega, and M. Hashibe Cystectomy for bladder cancer: a contemporary series J Urol 165 2001 1111 1116 (Pubitemid 32210214)
15. S. Madersbacher, W. Hochreiter, and F. Burkhard Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy J Clin Oncol 21 2003 690 696 (Pubitemid 46621904)
16. R.E. Hautmann, J.E. Gschwend, R.C. de Petriconi, M. Kron, and B.G. Volkmer Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era J Urol 176 2006 486 492 discussion 491-2 (Pubitemid 43927871)
17. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866 (Pubitemid 37025405)
18. N.P. Munro, S.K. Sundaram, and P.M. Weston A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK Int J Radiat Oncol Biol Phys 77 2010 119 124
19. S. Kotwal, A. Choudhury, and C. Johnston Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center Int J Radiat Oncol Biol Phys 70 2008 456 463
20. P. Zehnder, U.E. Studer, and E.C. Skinner Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study J Urol 186 2011 1261 1268
21. N.D. James, S.A. Hussain, and E. Hall Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004) J Clin Oncol 28 Suppl 15 2010 [abstract]
22. A. Horwich, D. Dearnaley, and R. Huddart A randomised trial of accelerated radiotherapy for localised invasive bladder cancer Radiother Oncol 75 2005 34 43 (Pubitemid 40616792)
23. A.L. Zietman, D. Sacco, and U. Skowronski Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors J Urol 170 2003 1772 1776 (Pubitemid 37254925)
24. J.A. Efstathiou, K. Bae, and W.U. Shipley Late pelvic toxicity following bladder-sparing therapy in patients with invasive bladder cancer: analysis of RTOG 8908, 9506, 9706, 9906 J Clin Oncol 27 2009 4055 4061
25. O. Caffo, G. Fellin, U. Graffer, and L. Luciani Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire Cancer 78 1996 1089 1097 (Pubitemid 26284875)
26. L. Henningsohn, H. Wijkstrom, P.W. Dickman, K. Bergmark, and G. Steineck Distressful symptoms after radical radiotherapy for urinary bladder cancer Radiother Oncol 62 2002 215 225 (Pubitemid 34286455)
27. W.J. Lynch, B.J. Jenkins, C.G. Fowler, H.F. Hope-Stone, and J.P. Blandy The quality of life after radical radiotherapy for bladder cancer Br J Urol 70 1992 519 521
28. J.L. Lagrange, C. Bascoul-Mollevi, and L. Geoffrois Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015) Int J Radiat Oncol Biol Phys 79 2011 172 178
29. P.J. Hoskin, A.M. Rojas, M.I. Saunders, S.M. Bentzen, and K.J. Motohashi Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial Radiother Oncol 91 2009 120 125
30. A. Choudhury, L.D. Nelson, and M.T. Teo MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer Cancer Res 70 2010 7017 7026